LABCORP HOLDINGS INC.

Alpha Score of 39 reflects weak overall profile with moderate momentum, poor value, moderate quality. Based on 3 of 4 signals — score is capped at 90 until remaining data ingests.

Labcorp Holdings Inc. is a leading provider of laboratory services, operating through two primary segments: Diagnostics Laboratories and Biopharma Laboratory Services. It delivers a comprehensive array of diagnostic tests, including blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C, vitamin D, microbiology cultures, and substance-abuse screenings. The company also specializes in advanced esoteric testing, such as gene-based diagnostics, molecular residual disease testing for cancers like breast, lung, and colon, and innovative blood tests to rule out Alzheimer's-related amyloid pathology. Labcorp Holdings Inc. supports physicians, hospitals, pharmaceutical firms, researchers, and patients with routine and complex clinical lab services, including oncology, genomic testing, and digital pathology platforms. These offerings enable clear decision-making in healthcare, from primary care to specialized biopharma research. Headquartered in Burlington, North Carolina, the company maintains an extensive network of patient service centers and collaborations to advance diagnostic efficiency and patient outcomes.